Treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine is comparable in patients with type 2 diabetes mellitus after switching from insulin glargine or insulin degludec: a post-marketing safety study
Author:
Affiliation:
1. Medicines Development Unit-Japan, Eli Lilly Japan K. K, Kobe, Japan
Publisher
Informa UK Limited
Subject
General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/03007995.2020.1834374
Reference30 articles.
1. World Health Organization (WHO). Global report on diabetes; 2016. Available from: https://www.who.int/diabetes/global-report/en/.
2. Global Prevalence of Type 2 Diabetes over the Next Ten Years (2018-2028)
3. Increasing Number of People with Diabetes in Japan: Is This Trend Real?
4. Japanese Clinical Practice Guideline for Diabetes 2016
5. Improvement of glycemic control and quality-of-life by insulin lispro therapy: Assessing benefits by ITR-QOL questionnaires
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Treatment Patterns, Effectiveness, and Safety of Originator Insulin Glargine versus Insulin Glargine-yfgn within the Veterans Health Administration;Pharmacoepidemiology;2024-03-01
2. The Impact of Mandatory Nonmedical Switching From Originator to Biosimilar Insulin Glargine;Clinical Therapeutics;2022-07
3. New Insulins, Biosimilars, and Insulin Therapy;Diabetes Technology & Therapeutics;2022-04-01
4. Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future;Current Medical Research and Opinion;2021-07-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3